Cancer Biopsy Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

Description

The Global Cancer Biopsy Market was valued at USD 21.5 billion in 2023 and is projected to expand at a CAGR of 8.4% from 2024 to 2032. This growth is fueled by the rising prevalence of cancer and advancements in diagnostic technologies, particularly biopsies.

Techniques like liquid biopsy and next-generation sequencing (NGS) are gaining traction for their precision and minimally invasive approach. These advancements are revolutionizing cancer diagnostics, offering methods that are both less invasive and more accurate for disease detection and monitoring. A 2019 report from the National Cancer Institute (NCI) highlighted that liquid biopsies could detect genetic mutations in over 70% of advanced cancer cases, aiming to bolster early detection, tailor treatment strategies, and enhance patient outcomes.

Heightened awareness of inherited oncology disorders and the significance of genetic testing is amplifying demand. These technologies facilitate early detection and personalized treatments, leading to better patient outcomes. Consequently, there's a pronounced focus on targeted cancer therapies, harnessing insights from advanced biopsy techniques.

The overall cancer biopsy industry is classified based on biopsy type, product and services, cancer type, end-user, and region.

The tissue biopsy segment, projected to grow at a CAGR of 8.3% during the forecast period, encompasses needle biopsies, surgical biopsies, and other tissue types. Its market dominance stems from its status as the gold standard in cancer diagnosis, delivering highly accurate and dependable results. Tissue biopsies provide in-depth histological and molecular insights, crucial for precise tumor characterization and subsequent treatment decisions. Their reliability spans various cancers, including breast, lung, and prostate, bolstered by advancements in minimally invasive techniques and imaging technologies that enhance both precision and safety.

The breast cancer segment is witnessing surging demand, predicted to hit USD 8.7 billion by 2032. The global uptick in breast cancer cases underscores the pivotal role of biopsies in its management. Data from the NCI indicates a steady 0.5% annual rise in breast cancer incidence from 2013 to 2018, culminating in an estimated 297,790 new cases in 2023. This escalating prevalence accentuates the pressing need for advancements in detection, diagnosis, and treatment, fueling the demand for biopsies. Furthermore, robust research and clinical evidence for advanced biopsy techniques amplify their demand in this segment, underscoring its significance in tackling the global breast cancer burden.

Asia Pacific cancer biopsy market is set for swift expansion, with a CAGR of 8.7% through 2032. The region's growing embrace of genetic testing underscores the vital need for timely and accurate cancer detection. This trend propels the demand for advanced biopsy techniques, which promise precise diagnoses and effective treatments. Additionally, bolstered by government initiatives and healthcare investments, the region's enhanced accessibility to cutting-edge biopsy technologies is a significant driver of this market growth.

Product Code: 10995

Chapter 1 Methodology and Scope

1.1 Market scope and definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Rising prevalence of cancer
  - 3.2.1.2 Technological advancements in cancer biopsy techniques
  - 3.2.1.3 Rising awareness in inherited oncology disorders and genetic testing
  - 3.2.1.4 Expansion of research and development
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 High cost of biopsy devices
  - 3.2.2.2 Stringent regulatory requirements
3.3 Growth potential analysis
3.4 Technology landscape
3.5 Future market trends
3.6 Regulatory landscape
3.7 Porter's analysis
3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Biopsy Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Tissue biopsy
- 5.2.1 Needle biopsy
- 5.2.2 Surgical biopsy
- 5.2.3 Other tissue biopsy types
5.3 Liquid biopsy
- 5.3.1 Circulating tumor cells (CTCs)
- 5.3.2 Circulating tumor DNA (ctDNA)
- 5.3.3 Other liquid biopsy types
5.4 Image-guided biopsy
5.5 Other biopsy types

Chapter 6 Market Estimates and Forecast, By Products and Services, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Products
- 6.2.1 Biopsy needles/ guns
  - 6.2.1.1 Fine needle aspiration (FNA)
  - 6.2.1.2 Core needle biopsy (CNB)
  - 6.2.1.3 Vacuum-assisted biopsy devices
- 6.2.2 Biopsy forceps
  - 6.2.2.1 General biopsy forceps
  - 6.2.2.2 Hot biopsy forceps
- 6.2.3 Kits and reagents
- 6.2.4 Consumables
6.3 Services

Chapter 7 Market Estimates and Forecast, By Cancer Type, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Breast cancer
7.3 Colorectal cancer
7.4 Stomach cancer
7.5 Lung cancer
7.6 Liver cancer
7.7 Prostate cancer
7.8 Ovarian cancer
7.9 Other cancer types

Chapter 8 Market Estimates and Forecast, By End-user, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Hospitals
8.3 Cancer research centers
8.4 Diagnostic centers
8.5 Research and academics

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.3.7 Rest of Europe
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

10.1 ANGLE plc.
10.2 BD (Becton, Dickinson and Company)
10.3 Biodesix (Integrated Diagnostics)
10.4 Chronix Biomedical, Inc (Oncocyte Corporation )
10.5 Devicor Medical Products, Inc.
10.6 GRAIL, Inc.
10.7 Hologic, Inc.
10.8 Illumina, Inc.
10.9 IZI Medical Products
10.10 Lucence Health Inc.
10.11 Myriad Genetics, Inc.
10.12 Oncimmune Holdings PLC
10.13 Personal Genome Diagnostics Inc.
10.14 QIAGEN N.V.